Guri Solum
Papers
1
Total Citations
30
H-Index
1
About
Guri Solum is a pioneering translational researcher whose work sits at the intersection of immunotherapy and urologic oncology, with a primary focus on developing personalized dendritic cell (DC) vaccines for high-risk prostate cancer. Her most impactful contribution is the landmark long-term Phase I/II first-in-man study, which demonstrated the safety and feasibility of administering an adjuvant DC vaccine to patients following radical prostatectomy. This work, cited over 30 times, provided critical early evidence that personalized immunotherapy could potentially reduce the risk of biochemical relapse—a key precursor to metastatic disease—in patients with aggressive prostate cancer. By targeting residual disease in the adjuvant setting, Solum’s research has helped shift the paradigm toward earlier, preventative immune intervention rather than waiting for recurrence. Her findings have laid essential groundwork for larger efficacy trials and underscore the promise of leveraging a patient’s own immune system to improve long-term outcomes in high-risk prostate cancer. Through this pioneering clinical work, Solum has established herself as a key figure in the effort to make personalized cancer vaccines a viable treatment reality.
Research Focus
Key Achievements
Top Papers
- 1